25 research outputs found

    Novelty in bacteria source production and concrete binders in self-healing cementitious samples

    No full text
    One of the challenges associated with creating bacterial-concrete systems capable of biomineralizing CaCO3 to fill cracks is the high pH environment of the hydrated cement paste. In this study two approaches to address this challenge were investigated: (i) the use of calcium sulfoaluminate (CSA) cement, which develops a naturally lower pH, and (ii) the use of non-axenic bacterial cultures, which may facilitate growth of bacterial strains more resilient to harsh alkaline conditions. Axenic B. subtilis and a non-axenic bacterial system from soil were produced and utilized in ordinary portland cement (OPC) and CSA samples. The mechanical properties, water absorption, calcium carbonate precipitation capability, and survivability of bacteria were investigated. The highest B. subtilis and soil bacteria viability was obtained through use of CSA cement and may enable greater later age crack healing potential than mixtures using OPC. Incorporation of axenic bacteria resulted in increased bacteria survivability in the mortar samples when compared to non-axenic bacteria mixes. However, in both cementitious systems, use of B. subtilis and soil bacteria led to similar improvements, suggesting that non-axenic cultures may be used in concrete effectively

    Data for Novel Alternative Cement Binders for Highway Structures and Pavements

    No full text
    The contents of data file include raw data for all the data plots included in the final report titled Novel Alternative Cement Binders for Highway Structures and Pavements. The excel spreadsheets were named based on chapter numbers in the final report.The ubiquity and the necessity of concrete infrastructure prompts innovation in addressing the global challenge of meeting societal needs in the most sustainable and economical ways possible. Increasing the use of non-portland cements or “alternative cementitious materials” (ACMs) is increasingly of interest due to their special properties and to their potential to reduce the environmental footprint of concrete. The special properties of ACMs may vary by material but include rapid setting, rapid strength development, higher ultimate strength, improved dimensional stability and increased durability in aggressive environments. The increased strength and increased durability further contribute to enhanced service life which can help offset initially higher materials costs, and also to enhanced sustainability. In the past, most ACMs have primarily been used in specialty limited applications and some of them have been shown in lab-scale studies to be feasible for the partial or full replacement of traditional portland cements used in concrete. However, there is limited understanding of the scalability of construction with these material systems, their long-term performance and durability in a range of environments, and their structural response when subjected to transportation-relevant loading conditions. This data presents the results from the comprehensive investigation of the applications of these commercially available ACMs in durable and sustainable transportation infrastructure, which include the early-age and long-term material properties as well as complete multi-scale durability investigations.Office of Infrastructure Research & Development, Federal Highway Administration, 6300 Georgetown Pike, McLean, VA 22101-2296. Grant number: DRFH61-14-H-000

    FOLFIRINOX for advanced pancreatic cancer: the Princess Margaret Cancer Centre experience

    Get PDF
    BACKGROUND: FOLFIRINOX has been shown to significantly increase both overall survival (OS) and progression-free survival (PFS) in metastatic pancreas cancer. There is limited data regarding the treatment of locally advanced pancreatic cancer. We present a retrospective study of patients with both locally advanced and metastatic pancreas cancer using FOLFIRINOX as first-line therapy in our centre. METHODS: This is a retrospective review of patients treated with FOLFIRINOX for pancreatic cancer at Princess Margaret Cancer Centre, between December 2011 and July 2014. The primary objective was to evaluate the efficacy and safety of FOLFIRINOX when used with dose modifications. RESULTS: One hundred two patients were identified; 66 metastatic and 36 locally advanced. Sixty-eight per cent of patients initiated treatment with a dose reduction. The median (95% CI) OS in the metastatic group was 13.1 (6.3–16.1) months with full dose and 12.9 (10.3–30.1) months with modified dose. The median (95% CI) OS in the locally advanced group was 11.1 (6.1–not reached) months with full dose and 23 (not reached–not reached) months with modified dose. The median (95% CI) PFS in the metastatic group was 6.2 (4.9–15.2) months with full dose and 8.7 (5.7–12.9) months with modified dose. The median (95% CI) PFS in the locally advanced group was 11.1 (3.1–not reached) months with full dose and 10.4 (6.8–not reached) months with modified dose. Grade 3/4 haematologic adverse events were observed in 43% of patients. Grade 3/4 non-haematologic adverse events were observed in 28% of patients. Patient well-being significantly improved from baseline to cycle 4 (P=0.002). CONCLUSIONS: Efficacy was achievable with dose-modified FOLFIRINOX in daily setting. The safety of FOLFIRINOX remains a concern with a high rate of grades 3 and 4 neutropaenia despite dose reduction
    corecore